Pipeline

Research programs of Clayton Foundation and its supporting organizations have led to several FDA approved drugs, medical devices and diagnostic assays along with the following pipeline in development by our licensees.

Available for Licensing
(Pre-Clinical & Early Stage)

DHS Fc Domain

Fc domain for antibody half-life extension

Animal POC (Download PDF)

HI P. Goldsteinii

Indication: Osteoporosis and Obesity

Preclinical (Download PDF)

YESS-KI

Diagnostic for Kinase Inhibitor Therapy

Research (Download PDF)

Phase Agnostic Stimulation

Closed-loop bioelectric therapy

Research (Download PDF)

Cymirafen

LGR targeting therapeutic

Preclinical (Download PDF)

HDAC inhibitors for TB

Valproic acid to treat TB

Drug repurposing (Download PDF)

Partnered (Pre-Clinical & Clinical)

Dengue Virus Vaccine

Indication: 4 serotype dengue vaccine

IND in preparation

Chikungunya Virus Vaccine

Indication: vaccine to chikungunya

IND enabling studies

Zika Virus Vaccine

Indication: vaccine to zika

IND enabling studies

RT-200

Indication: Type II Diabetes

Advanced Preclinical

RT-300

Indication: Congestive Heart Failure

Preclinical

RT-400

Indication: Acute decompensated heart failure

Preclinical

GrB-Fc-SD1

Indication: Mesotheliomas & Pancreatic Cancers

Preclinical

GrB-Fc-IT4

Indication: Breast and other solid tumors

Preclinical

GrB-Fc-VEGF

Indication: Wet AMD & Choroidal Neovascularization

Preclinical

JamC mAb

Indication: B Cell Lymphomas

Animal in vivo POC

Olfml3 mAb

Indication: Metastatic breast cancer

Animal in vivo POC

VT-101

Indication: Solid Tumors

Phase I